RxDoctor Payments Data

Natasha Worthington, PA

Family Medicine · Dublin, PANPI 1467508101

Payments from drug & device makers

$9,738in general payments, 2019–2025

Across 529 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Astellas Pharma US Inc$935
  • Pfizer$730
  • GSK$666
  • plus $4K from 32 others

What the payments were for

  • Speaking & faculty fees$140%
  • Food & beverage$9,19894%
  • Education$5275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,738 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$31,167
Medicare patients
179
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$53,059
TrulicityDulaglutide25$23,366
JardianceEmpagliflozin18$21,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,365
MounjaroTirzepatide13$13,416
Lagevrio (Eua)Molnupiravir12$9,075
MyrbetriqMirabegron16$8,806
EliquisApixaban12$7,512
Tresiba Flextouch U-100Insulin Degludec12$6,331
PaxlovidNirmatrelvir/Ritonavir15$5,717
VascepaIcosapent Ethyl13$5,005
Albuterol Sulfate HfaAlbuterol Sulfate81$2,998
Atorvastatin Calcium149$1,978
Levothyroxine Sodium155$1,933
Omega-3 Acid Ethyl Esters17$1,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,514$53,05942 claims
Lilly USA, LLCTrulicity, Mounjaro$542$36,78138 claims
Boehringer IngelheimJardiance$558$21,68118 claims
GSKTrelegy Ellipta$666$17,36522 claims
PfizerEliquis, Paxlovid$730$13,22927 claims
MerckLagevrio (Eua)$104$9,07512 claims
Astellas Pharma US IncMyrbetriq$935$8,80616 claims
AbbVieSynthroid$1,145$41815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Dublin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →